Virtu Financial LLC Buys Shares of 6,224 Revolution Medicines, Inc. (NASDAQ:RVMD)

Virtu Financial LLC purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,224 shares of the company’s stock, valued at approximately $272,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. IFP Advisors Inc acquired a new position in Revolution Medicines in the fourth quarter valued at about $34,000. Quarry LP acquired a new position in shares of Revolution Medicines in the 3rd quarter valued at approximately $82,000. Farther Finance Advisors LLC increased its stake in Revolution Medicines by 368.3% during the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock worth $90,000 after purchasing an additional 1,613 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in Revolution Medicines by 521.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company’s stock worth $165,000 after buying an additional 3,178 shares during the period. Finally, Avanza Fonder AB bought a new position in Revolution Medicines in the fourth quarter valued at approximately $173,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RVMD. UBS Group raised their price objective on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Guggenheim lifted their price target on Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Wedbush reaffirmed an “outperform” rating and set a $67.00 price objective on shares of Revolution Medicines in a research report on Thursday, February 27th. HC Wainwright increased their price objective on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Finally, Needham & Company LLC cut their target price on Revolution Medicines from $60.00 to $59.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Twelve investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $66.31.

Revolution Medicines Trading Up 1.0 %

Shares of RVMD opened at $38.10 on Friday. The company’s fifty day simple moving average is $40.38 and its 200 day simple moving average is $45.59. Revolution Medicines, Inc. has a 1-year low of $29.55 and a 1-year high of $62.40. The company has a market cap of $7.08 billion, a price-to-earnings ratio of -10.61 and a beta of 1.46.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, research analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, insider Mark A. Goldsmith sold 11,738 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the transaction, the insider now directly owns 441,564 shares in the company, valued at $17,238,658.56. The trade was a 2.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jack Anders sold 1,864 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now owns 115,006 shares of the company’s stock, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,660 shares of company stock valued at $650,406 over the last 90 days. 8.00% of the stock is currently owned by insiders.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.